MEDICINOVA, INC. (NASDAQ:MNOV) Files An 8-K Submission of Matters to a Vote of Security Holders

ME Staff 8-k
-
0

MEDICINOVA, INC. (NASDAQ:MNOV) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07

Submission of Matters to a Vote of Security Holders.

MediciNova, Inc. (the Company) held its 2017 annual meeting of
stockholders on June 8, 2017 (the Annual Meeting). The Company
filed its definitive proxy statement for the proposals voted upon
at the Annual Meeting with the Securities and Exchange Commission
on April 27, 2017.

At the close of business on April 13, 2017, the record date of
the Annual Meeting, the Company had 34,540,453 shares of common
stock issued and outstanding. The holders of a total of
25,449,727 shares of common stock were present at the Annual
Meeting, either in person or by proxy, which total constituted a
quorum of the issued and outstanding shares on the record date of
the Annual Meeting.

Set forth below are the results of the matters submitted for a
vote of stockholders at the Annual Meeting

(a)

To elect a Class I Director nominee named below to serve
until the 2020 Annual Meeting of Stockholders. The named
nominees were so elected, with the votes thereon at the
Annual Meeting as follows:

Final Voting Results

Nominee

For

Withheld

Broker Non-Vote

Jeff Himawan

23,199,272

992,666

1,257,789

(b)

To ratify the selection by the Audit Committee of the
Companys Board of Directors of BDO USA, LLP as the
independent registered public accounting firm of the
Company for its fiscal year ending December 31, 2017.
This proposal was approved, with the votes thereon at the
Annual Meeting as follows:

Final Voting Results

For

Against

Abstain

Broker Non-Vote

24,662,983

355,473

431,271

(c)

To approve an amendment to the 2013 Equity Incentive Plan
to increase the number of shares of Common Stock issuable
under the Plan by 1,200,000 shares. This proposal was
approved, with the votes thereon at the Annual Meeting as
follows:

Final Voting Results

For

Against

Abstain

Broker Non-Vote

22,543,865

1,113,591

534,682

1,257,589


About MEDICINOVA, INC. (NASDAQ:MNOV)

MediciNova, Inc. is a biopharmaceutical company. The Company is focused on acquiring and developing small molecule therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It is focused on its development activities on MN-166 (ibudilast) for neurological disorders and MN-001 (tipelukast) for fibrotic diseases, such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). Its pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers. Its MN-166 is an oral, anti-inflammatory and neuroprotective agent, which inhibits macrophage migration inhibitory factor (MIF) and certain phosphodiesterases (PDEs). Its MN-001 is an orally bioavailable small molecule compound. Its MN-221 is a highly selective B2-adrenergic receptor agonist being developed for the treatment of acute exacerbations of asthma.